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Health, Human Rights and the Pharmaceutical Industry
by Gerald Montgomery
PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT
AND PUBLIC HEALTH, World Trade Organization, 2 September, 2003:
We are committed to helping countries that are experiencing public health crises. We want to find a real
solution to problems that prevent Members from being able to address health problems associated with access
to pharmaceuticals. We want all Members to be able to use the full flexibility of the TRIPS Agreement to
help provide their citizens access to affordable medicines in times of crises.
We note that the Doha TRIPS declaration recognizes that the exclusive rights provided by patents are an
important incentive to development of new drugs. Patents provide market incentives for innovators to risk
time, energy and resources to develop and bring to market new technology. A system of patent rights and
enforcement of those rights for pharmaceuticals provides numerous benefits to society; the availability of
exclusive patent rights for pharmaceutical products spurs research and development of new medicines, including
those resulting from biotechnology, to treat and cure diseases ….
The pharmaceutical industry is a crucial touchstone in the discussion of corporate responsibility
to promote human rights. This relationship is, however, problematic at best and, at worst work in
opposition to each other. At the same time that drug producers are instrumental in promoting a
basic level of human welfare, the outlook of major pharmaceutical corporations are mitigated by
unfiltered lenses of profit. With hundreds of millions of dollars spent on research and development,
patenting, and marketing, they understandably develop strategies for handling reoccurring costs. But
should a morally responsible international community redirect these costs to the developing world
or ask consumers in the global North to endure “artificially high” prices to offset gross inequalities?
Alternatively, is there means to set reasonable prices based on the economic reality of each country?
The broad overriding theme of the selection of texts below will be that TRIPS (Trade-Related
Aspects of Intellectual Property Rights) has greatly affected the supply of drugs to the Third World.
This is because, among other things, TRIPS is based on the idea that artists, entrepreneurs and
inventors have a legal right to protect profits derived from their ideas. An important practical
implication of this belief is that it forces competitors to adhere to strict manufacturing guidelines,
greatly affecting global drug supply. TRIPS, then, is a legal framework that creates standards that
protects these works.
However in the Uruguay round of talks, TRIPS was seen as disproportionately bolstering the
legal rights of Northern countries. Characteristic of this, in the Uruguay round of talks Southern
states argued that TRIPS promotes the interests of drug manufacturing Northern countries. In an
effort to mediate these inequalities other international organizations such as the World Health
Organization recommend policies that ensure the availability of drugs at affordable prices in
documents like the Doha Declaration. Reflecting the political tenor and policy consequences of
these debates, this bibliography organizes itself according to the following categories: pharmaceutical
patent issues, company relations with developing countries, research, country cases, TRIPS, general,
and laws, initiative, and policy.
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Basic Resources
Chien, Colleen. 2003. “Cheap Drugs at What Price to Innovation: does the compulsory licensing of
pharmaceuticals hurt innovation?.” Berkeley Technology Law Journal 18(3): 853-903
<http://papers.ssrn.com/sol3/papers.cfm?abstract_id=486723.>
Abstract: The patent system is built on the premise that patents provide an incentive for innovation by offering a
limited monopoly to patentees. The inverse assumption that removing patent protection will hurt innovation has
largely prevented the widespread use of compulsory licensing—the practice of allowing third parties to use patented
inventions without patentee permission…. The author comments on the use of compulsory licensing to reduce the
price of AIDS and other drugs for developing countries. I suggest that, based on past experience, compulsory
licenses need not result in a decline in innovation and that this policy option for increasing access to medicines
deserves greater exploration.
De Silva, Allenson. 2002. Pharmaceutical Drugs & Health: a Critique. Colombo, Sri Lanka: Centre
for Society & Religion.
Granville, Brigitte. 2002. The Economics of Essential Medicines. Washington, DC : Royal Institute
of International Affairs; distributed worldwide by the Brookings Institution.
Leufkens H.G.M.; F.M. Haaijer-Ruskamp; and A. Bakker. 1995. The Future of Medicines in Health
Care: Scenario Report (Commissioned by the Steering Committee on Future Health Scenarios;
Scenario Committee on Medicine in Health Care; WHO Collaborating Center for Drugs Policy
Studies). Boston: Kluwer Academic Publishers.
McGregor, Alan. 1997. “Couterfeit Drugs Flood Developing World.” Lancet 350(909): 1690-1694.
Pérez-Casas, Carmen and Emilia Herranz. 2001. “Pricing of Drugs and Donations: options for
sustainable equity pricing.” Tropical Medicine & International Health 6(11): 960-965.
Abstract: Effective medicines exist to treat or alleviate many diseases which predominate in the developing world
and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines.
Increasingly, drug donations are required of drug companies, but these are often limited in time, place or use.
Measures exist which are more sustainable and will have a greater positive impact on people’s health. Principally,
these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards
to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global
and regional procurement; and supporting the production of quality generic drugs by developing countries through
voluntary licenses if needed, and facilitating technology transfer.
Ratanawijitrasin, Sauwakon; Stephen B. Soumerai; and Krisantha Weerasuriya. 2001. “Do National
Medicinal Drug Policies and Essential Drug Programs Improve Drug Use?” Social Science &
Medicine 53(7): 831-844.
Abstract: Conducts a critical review and synthesis of international literature in an attempt to define the state of
knowledge regarding drug policy effects on drug use. Tests whether the development of national policies and
regulations by the governments of developing countries increase the affordability, supply safety and rational use of
pharmaceuticals.
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Stokes, Bruce. 2003. “It’s All About the Medicine.” National Journal 35(29): 2368-2370.
This article presents an effort to dispel myths about the problems developing countries have in
accessing low cost drugs. In doing so the article describes why the U.S. is deadlocked with the
international community on important parts of the agenda of the upcoming Doha round of
talks.
Weissman R. 1999. “AIDS Drugs for Africa.” Multinational Monitor 20(September): 9-14.
Documents the course of the dispute between the U.S. government and the South African
government over providing affordable drugs to the poor. Interestingly, the article argues that
South Africa and many other African nations are rendered politically and domestically unstable
from high AIDS coupled with unaffordable drug therapies. The conclusion is that the laws and
practices of major drug exporting countries such as the U.S. are used by pharmaceutical
companies to profit at the expense of developing countries and their populations.
Winestock, Geoff and Helene Cooper. 2001. “Activists Outmaneuver Drug Makers at WTO.” Wall
Street Journal - Eastern Edition (November 14): A2.
World Health Organization. 1999. Marketing Authorization of Pharmaceutical Products With
Special Reference to Multisource (Generic) Products: a Manual for a Drug Regulatory Authority.
Geneva: World Health Organization.

Company Relations With Developing Countries
“Drug Makers Hope to Profit From WTO Decision on Medications.” 2003. Health & Medicine
Week (October 27): 331-334.
Abstract: Reports on the efforts of the Brazil-based drug maker Cristalia Acquisition Corp. to try to profit from
the World Trade Organization’s agreement allowing impoverished nations to import copied patented medicines to
fight killer diseases. Benefits of the agreement for the company; Background of Cristalia; Criticism over the ability
of Brazil to produce enough generic drugs for countries that need them.
Global Partnerships: Humanitarian Programs of the Pharmaceutical Industry in Developing
Nations. 2003. Washington, D.C.: Pharmaceutical Research and Manufacturers of America. <
http://world.phrma.org/global.partnership.2003.pdf.>
“Pharmaceutical Company Honored With First Ever Pro Bono Partner Award.” 2003. Biotech Week:
14.
This article highlights the growing number of U.S. pharmaceutical companies that perform pro
bono work fusing the talents of public and private enterprises. Reports on the presentation of
CorporateProBono.Org’s (CPBO) Pro Bono Partner Award to Abbott Laboratories (ABT) Inc.
recognizing its work with Baker and McKenzie and the Midwest Immigrant and Human Rights
Center to provide legal counseling to immigrants and career counseling to high school students.
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“Pilot Program Launched to Expand Access to Medicines in Poorest Countries.” 2003. AIDS
Weekly (February 17): 16-18.
Reports on the launch of a pilot program for expanding access to needed medicines for AIDSinfected people in developing countries by Pharmacia Corp. Also highlights the partnership of
the company with International Dispensary Association Foundation to grant non-exclusive
licenses to generic pharmaceutical companies for AIDS drug Delavirdine.
“Progress Reported in Cutting AIDS Drug Prices for Poor Nations.” 2003. AIDS Weekly (February
17): 35-37.
Reports on the progress made by global business leaders in making cheaper AIDS drugs
available in developing countries. Information covered includes a grant announcement by
founder of Microsoft Corp. Bill Gates, for funding such medical researches in developing
countries; concerns of the U.S. pharmaceutical companies over the protection of drug patents in
these nations; reason why charitable institutions have to work really hard in developing
countries.
Agrawal, Madhu. 1999. Global Competitiveness in the Pharmaceutical Industry: the
Effect of National Regulatory, Economic, and Market Factors. New York: Haworth Press.
Bale, Harvey E. “Are International Pharmaceutical Companies Doing Enough to Provide Low-Cost
AIDS Drugs to Developing Countries?” International Debates 1(4): 108-113.
Presents the author’s views in favor of international pharmaceutical companies’ steps in
providing low-cost AIDS drugs in developing countries. Role of pharmaceutical company in
developing effective drugs to prevent the disease; Pricing policy followed by pharmaceutical
company while subsidizing drugs for AIDS.
Brugha, Ruairi. 2003. “Antiretroviral Treatment in Developing Countries: the Peril of Neglecting
Private Providers.” British Medical Journal; International Edition 326(7403): 1382.
Abstract: Increased access to antiretroviral drugs is vital to maintain developing countries with high rates of
HIV infection. But unless treatment is properly controlled, these drugs could rapidly become useless.
Note: The increasing problem of delivering antiretroviral drugs being handed out in poorer
countries is the increased likelihood of the indiscriminate use could lead leading to increased to
resistance if drug resistance if the supply and usage s are not regulated. The article includes
several case studies from Africa (Uganda and Senegal) and identifies methods (such as working
with the private sector) to alleviate this problem.
Carpenter, Dave. 2003. “Do-Good Pharmas?” Hospitals & Health Networks 77(10): 48-51.
Provides a discussion of Pfizer as an example of how a company can bridge the gap between
profit margins and social responsibility in providing access to health care in developing
countries.
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Cohen, Jillian Clare. 2001. Pharmaceutical Napsters?: a Comparative Study of State Response to the
Pharmaceutical Imperatives on the agreement on Trade-Related Aspects if Intellectual Property
Rights. Ann Arbor, MI: University of Michigan Press.
Dugger, Celia W. 2001. “A Catch-22 on Drugs for the World’s Poor; The Right to make generics,
but not the means to do it.” New York Times (November 16): W1.
A discussion of the inability of poor countries to manufacture low cost drugs, but do not have
the means to do so and are not allowed to import them from countries that do so.
Fleck, Fiona. 2003. “No Deal in Sight on Cheap Drugs for Poor Countries.” British Medical Journal;
International Edition 326(7387): 465.
Notes: This article describes trade negotiations held for the purpose of hammering out an
agreement on the importation or creation of cheap drugs for the developing world. The United
States’ blocked agreements to allow third world countries the right to produce low cost drugs
because of concern over patent and intellectual property issues.
Ford, Nathan. 2003. “Public Health and Company Wealth: When Public Protest at the Price of
AIDS Drugs Reached a Peak, Pharmaceutical Companies Seemed to Take Note, but the
Developing World’s Health Problems Will Never Really Be Tackled As Long As Remedies for
Western Afflictions Remain More Profitable.” British Medical Journal; International Edition
326(7402): 1296.
This editorial reviews the availability and pricing of drugs in third world countries with those of
the developed world. Argues that countries are responsible for ensuring health care and
companies supplying drugs need to do take a more responsible role as a partner in the fight
against massive endemics such as aids.
Goodman, Sally. 2003. “Poor Nations Push for Right to Produce Cheap Medicines.” Nature
411(6841): 982-986.
Reports that developing countries have requested the modification of the global trading rules on
the distribution of medicines at the June 20, 2001 meeting of the World Trade Organization in
Geneva, Switzerland. Also covers the aim of trade-related aspects of intellectual property rights;
reaction of the United States delegates to the request.
Knodro, Wayne. 2003. “Canada Delays Legislation on Cheap Drugs.” Lancet 362(9397): 1729.
Abstract: This article focuses on how developing countries hoping to obtain cheap drugs from Canada to treat
AIDS, tuberculosis, malaria, and other diseases will have to wait longer than expected for access to cheap drugs
as internal debates have indefinitely delayed passage of the necessary legislation. Although the governing Liberal
party tabled legislation on cheap drugs for poor countries on Nov 6—weeks later than promised—it promptly
prorogued Parliament, dispatching the bill to death on the order paper, where it will have to be revived by the
Prime Minister-in-waiting—Paul Martin–after he assumes office.
Mattias Ganslandt; Keith E. Maskus; and Eina V. Wong. 2001. Developing and Distributing
Essential Medicines to Poor Countries: the DEFEND Proposal. Stockholm, Sweden: IUI, the
Research Institute of Industrial Economics <http://www.iui.se/wp/wp552/iuiwp552.pdf>.
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Mytelka, Lynn Krieger. 1999. Competition, Innovation and Competitiveness in Developing
Countries. Paris: Development Centre, Organisation for Economic Co-operation and
Development.
Nullis, Clare. “Agreement on Access to Cheap Medicines Remains Elusive.” 2002. Associated Press
Dec. 12.
Silversides, Ann. 2003. “No Turning Back on Cheap AIDS Drugs for Poor Nations, U.N. Vows.”
CMAJ: Canadian Medical Association Journal 169(10): 1067.
Canada is trying to take the lead in changing drug patents for the purpose of exporting cheaper
drugs to developing countries with the hope that other wealthy countries will follow suit.
Thurow, Roger and Scott Miller. 2003. “Empty Shelves: As U.S. Balks on Medicine Deal, African
Patients Feel the Pain --- Big Drug Makers, Protecting Their Patents, Seek Limits To a Global
Trade Accord --- Searching for Insulin in Chad.” Wall Street Journal - Eastern Edition (June 2): A1.
Vastag, Brian. 2003. “Alarm Sounded on Fake, Tainted Drugs: Some Wholesalers Are a Weak Link
in a Dangerous Chain.” Journal of the American Medical Association 290(8): 1015-1017.
Weissman, Robert. 1999. “AIDS Drugs for Africa.” Multinational Monitor 20(9): 9-14.
Documents the course of the dispute between the U.S. government and the South African
government over providing affordable drugs to the poor. Interestingly, the article argues that
South Africa and many other African nations are rendered politically and domestically unstable
from high AIDS coupled with unaffordable drug therapies. The conclusion is that the laws and
practices of major drug exporting countries such as the U.S. are used by pharmaceutical
companies to profit at the expense of developing countries and their populations.
Country Cases
NA. 2004. “HIV Treatment As a Human Right - Learning From Thailand’s Experience.” Biotech
Week (March 3): 157.
Abstract: A new paper discusses the landmark legal case in Thailand where two people with HIV infections
successfully challenged a multinational pharmaceutical company for restricting access to a key antiretroviral drug
due to its high cost. Nathan Ford and colleagues from the organization Medecins Sans Frontieres, authors of the
viewpoint article which appeared in the journal “Lancet” discussed the processes behind this case and the
implications for drug access as a human rights issue in other developing countries.
Acharya, Rohini. The Emergence and Growth of Biotechnology Experiences in Industrialized and
Developing Countries. Cheltenham, UK; Northampton, Mass. E. Elgar, 1999.
Chaudhuri, Shubham; Pinelopi Koujianou Goldberg; and Panle Jia. 2003. The Effects of Extending
Intellectual Property Rights Protection to Developing Countries: a Case Study of the Indian
Pharmaceutical Market. Cambridge, MA: National Bureau of Economic Research.
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Patel, Vikram; and Chittaranjan Andrade. 2003. “Pharmacological Treatment of Severe Psychiatric
Disorders in the Developing World: Lessons From India.” CNS Drugs 17(15): 1071-1081.
Discusses the various cultural, biological, and availability issues pertaining to drug treatment in
areas of the world that do not have high incidences of mental disorders. Also comments on the
costs and treatment options in different regions of the world.
Thomas, L. G., III. 2001. The Japanese Pharmaceutical Industry: the New Drug Lag and the
Failure of Industrial Policy. Northampton, MA: Edward Elgar.

Laws, Initiative, Policy
“New WTO’s Policy to Protect Public Health Interests for Developing Countries. “ 2003. AsiaPacific Biotech News 7(22): 1452.
“WTO Panel Delays Decision on Cheap Drugs for Poor Countries.” 2003. Drug Week (September
26): 157-158.
Reports on the decision of the World Trade Organization (WTO) to delay a measure which will
give poor nations access to inexpensive generic drugs. Addresses the impact of the move on
poor nations; provides an overview of WTO rules regarding drug importation; and raises
concerns of U.S. pharmaceutical industries over drug smuggling.
Jacobzone, Stephane. 2000. Pharmaceutical Policies in OECD Countries: Reconciling Social
and Industrial Goals. Paris, France: Organisation for Economic Co-operation and Development.
Kapp, Clare. 2003. “World Trade Organisation Reaches Agreement on Generic Medicines: New
Deal Will Make It Easier for Poorer Countries to Import Cut-Price Generic Drugs Made Under
Compulsory Licensing.” Lancet 362(9386): 807.
Reports on an agreement within the World Trade Organization (WTO) which allows developing
countries stricken with HIV/AIDS, tuberculosis, and malaria to import cheap generic drugs.
The centerpiece of the agreement which concerned the waiver of the normal rule that
production of cheap generic drugs without the consent of the patent holder---compulsory
licensing--must be primarily for the domestic market; Resolution of the issue which ended a long
stalemate; Reactions from representatives of Africa, Brazil and other countries.
Loff, Bebe. 2002. “World Trade Organzation Wrestles With Access to Cheap Drugs Solution.”
Lancet 360(9346): 1670.
Reports on the World Trade Organization (WTO) meeting in Sydney, Australia to resolve how
poor nations can access cheap drugs. Meeting focusing on the agreement on Trade Related
Aspects of Intellectual Property Rights (TRIPS) governing domestic patent law and how it
influences access to pharmaceuticals; how the WTO softened trips stating that in cases of
epidemics it is permissible for governments to grant a compulsory license to manufacture drugs
still under patent.
118
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Moran, Alan. 2003. “Trade Laws and Pharmaceuticals.” IPA Review 53(4): 25-28.
Abstract: Focuses on trade aspects of intellectual property rights and provides a history of property rights. Also
addresses manufacturing and administrative costs for a vaccine as well as features of modern commerce and law
that prevent goods from being supplied more cheaply to developing countries.
Moran, Mary and Nathan Ford. 2003. “The G8 and Access to Medicines: No More Broken
Promises.” Lancet 361(9369): 1578.
Provides a detailed timeline of the previous conferences held by the G8 and their focus on the
affordable drugs to developing countries while looking forward to the upcoming G8 conference
in France.
Oxfam GB. 2001. Cut the Cost: Patent Injustice: How World Trade Rules Threaten the Health of
Poor People. Oxford: Oxfam.
http://www.oxfam.org.uk/what_we_do/issues/health/downloads/patentinjustice.pdf
Pfizer Inc. 2003. “Bringing Treatments, Developing Cures.” The Pfizer Journal: Perspectives on Health
Care and Biomedical Research. New York: Impact Communications.
Pollock, Allyson M. and David Price. 2003.”New Deal From the World Trade Organization May
Not Provide Essential Medicines for Poor Countries.” British Medical Journal; International Edition
327 (7415): 571-573.
Winestock, Geoff; and Helene Cooper. 2001. “Activists Outmaneuver Drug Makers at WTO.” Wall
Street Journal - Eastern Edition 238(96): A2.
World Health Organization. 1999. Marketing Authorization of Pharmaceutical Products With
Special Reference to Multisource (Generic) Products: a Manual for a Drug Regulatory Authority.
Geneva: World Health Organization. <http://www.who.int/medicines/library/qsm/manualon-marketing/multisource-contents.html>.

Pharmaceutical Patent Issues
“Institute for Oneworld Health Licenses Potent Therapy.” 2003. Drug Week (August 1).
This article reports that the pharmaceutical company Oneworld Health has licensed a novel class
of high-potency chemical compounds that may result in medicines for developing countries.
“Patents and HIV/AIDS Drugs.” International Debates 1(4): 104.
Abstract: Presents information about patent rights of manufacturing drugs to prevent HIV infection and AIDS
disease. Gives criteria of granting patent to a particular pharmaceutical company; factors determining the access to
essential drugs including drugs to treat HIV and other infections; and risk of HIV infection and AIDS in
developing countries.
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Correa, Carlos María. 2000. Integrating Public Health Concerns into Patent Legislation in
Developing Countries. Geneva: South Centre.
Cullet, Phillipe. 2003. “Patents and Medicines: the Relationship Between TRIPS and the Human
Right to Health. “ International Affairs 79(1): 139-60.
Interrogates the dilemma of the human right to health versus the idea of intellectual property
rights defined in TRIPS. It addresses the problem of how patents stand in the way of access to
drugs and gives solutions on what can be done to alleviate the disparity.
Cunningham, Ralph. 2003. “Health Crises Undermine Patent Rules.” Managing Intellectual Property
130: 43-50.
Abstract: Global patent issue -- ability of sick in developing countries to obtain patented medicines -- rights
under threat -- any relaxing of rules by WTO or TRIPs could result in fewer patents -- new legislation in Asian
countries -- new court takes over -- legislative tweaking -- effect of new laws in Pakistan unknown -- PCT
possibilities.
Vass, Alex. “WTO Relaxes Rule on Drug Patents.” British Medical Journal International Edition
323(7322):1146.
Abstract: International trade rules amount to institutional fraud and are preventing development in poor
countries, says a report published this week by a leading charity. Whereas trade has been one of the most powerful
driving forces in increasing prosperity for much of the world, millions of the world’s poor are being left behind, and
there is a widening of inequalities between the rich and poor. International trade rules, says the Oxfam report, are
“rigged in favour of the rich.” When developing countries export to rich country markets, they face tariff barriers
that are four times higher than those faced by rich countries. These barriers cost them $100bn (£70bn; 113bn) a
year, twice as much as they receive in aid. The report calls for an end to the universal application of the intellectual
property blueprint, and argues for the right of developing countries to retain shorter and more flexible systems of
patent protection.
Drug Research
“Phase II Trial With PRO 2000 to Prevent HIV Transmission Begins in Africa. “ 2003. Biotech Week
(July 16): 7.
Abstract: Indevus Pharmaceuticals, Inc., (IDEV) announced the initiation of a phase II clinical trial in Africa
assessing the safety of PRO 2000, a topically administered, vaginal microbicide designed to prevent infection by
the human immunodeficiency virus (HIV) that causes AIDS. This trial will provide safety data for PRO 2000
in a sexually active, developing country population, and PRO 2000 may be investigated in such African
populations in expanded phase III testing in the future,” said Dr. Bobby Sandage, executive vice president,
research and development at Indevus. Findings will build upon the growing clinical database for the drug.
“Study: Generic Drugs Helping AIDS Fight.” 2003. Health & Medicine Week (October 13): 627628.
Presents a report released by Doctors Without Borders on the use of generic drugs to treat
AIDS patients in developing countries. Citation of competition between generic and branded
120
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retroviral drugs; failure of most countries in meeting the goal of fighting and reversing the
epidemics; problem f discrimination of HIV-positive persons.
Bourinbaiar, Aldar S. and Vichai Jirathitikal. 2003. “Low-Cost Anti-HIV Compounds: Potential
Application for AIDS Therapy in Developing Countries.” Current Pharmaceutical Design 9(18):
1419-1432.
Abstract: Considerable progress has been made in recent years in the field of drug development against HIV.
However, the current cost of AIDS drugs is the main obstacle preventing their use in developing countries, where
95% of HIV infected patients reside. The average yearly price of AIDS therapy and related health care of
affected patients in the USA runs as high as $22,000...Even in the USA, patients without medical insurance
cannot afford the costly therapy. …This review summarizes the development and discovery of affordable and
potentially promising AIDS drugs.
Kettler, Hannah and Adrian Towse. 2002. Public Private Partnerships for Research and
Development: Medicines and Vaccines for Diseases of Poverty. London: OHE.
Lang, Trudie and Brian Greenwood. 2003. “The Development of Lapdap, an Affordable New
Treatment for Malaria.” Lancet Infectious Diseases 3(3): 162-168.
Abstract: There is much discussion on how new drugs can be developed for use in developing countries at a price
that makes them accessible to those who need them most… The partnership comprised between GlaxoSmithKline
(formerly SmithKline Beecham), the World Health Organization (WHO), and the UK’s Department for
International Development.
TRIPS
Abbott, Frederick M. 2002. WTO TRIPS Agreement and Its Implications for Access to
Medicines in Developing Countries. London: Commission on Intellectual Property Rights.
<http://www.iprcommission.org/papers/pdfs/study_papers/sp2a_abbott_study.pdf>.
Bale, H.E. 2000. TRIPS, Pharmaceuticals, and Developing Countries: Implications for Drug Access
and Drug Development. Geneva, Switzerland: International Federation of Pharmaceutical
Manufacturers Association.
Cullet, Phillipe. 2003. “Patents and Medicines: the Relationship Between TRIPS and the Human
Right to Health.” International Affairs 79(1): 139-60.
Abstract: Interrogates the dilemma of the human right to health versus the idea of intellectual property rights
defined in TRIPS. It addresses the problem of how patents stand in the way of access to drugs and gives solutions
on what can be done to alleviate the disparity. Access to drugs in developing countries is at present largely
influenced by the TRIPS Agreement. TRIPS compliance in the field of health requires substantial changes to
existing patent laws in some countries. These changes must be analyzed in the context of the spread of epidemics
like HIV/AIDS and in relation to other international obligations that states have, for instance, with regard to
the human right to health. Intellectual property rights treaties today have significant impacts on the realization of
some human rights like the right to health. Also examined are these issues from the point of view of human rights
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considering, in particular, the ways in which the relationship between human rights and intellectual property can be
improved in international law.
Lanoszka, Anna. 2003. “The Global Politics of Intellectual Property Rights and Pharmaceutical
Drug Policies in Developing Countries.” International Political Science Review 24: 181-198.
Abstract: One of the major characteristics of the emerging international economic order is the treatment of
intellectual property rights (IPRS). Developing country members are very concerned about the impact that the
World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS) will have on their economies. TRIPS emphasizes a property rights approach whereby private “owners”
of the inventions can restrict access on the basis of commercial considerations. As a consequence, higher prices for
pharmaceuticals and other healthcare inventions can prevent low-income consumers in developing countries from
obtaining life-saving medications and equipment. Many developing countries, however, lack the necessary financial
resources and have not yet developed appropriate competition rules to deal effectively with the challenges presented
by the TRIPS Agreement.
Lybecker, Kristina Marie. 2000. Counterfeit Pharmaceuticals: Product Piracy and the Transition to
Stronger Intellectual Proper. <http://www.lebow.drexel.edu/lybecker/piracy.doc>.
Macklin, Ruth. 2003. “Bioethics, Vulnerability, and Protection.” Bioethics 17(5-6): 472-487.
Abstract: …Vulnerable individuals and groups are subject to exploitation, and exploitation is morally wrong.
Multinational research invests in situations in which vulnerable people can be exploited even if they are not
harmed, and harmed even if they are not exploited. The types of multinational research likely to raise the most
ethical concerns are those in which the investigators or sponsors are from a powerful industrialized country or a
giant pharmaceutical company and the research is conducted in a developing country. In such a scenario, women
are particularly vulnerable. ...On the positive side, recent developments reveal a new awareness of exploitation and
efforts to enhance the ability of developing countries to protect themselves and their citizens from exploitation at the
hands of powerful sponsors of research. In addition, human rights principles are increasingly being used to monitor
the actions (or inaction) of governments regarding women’s reproductive rights and vulnerability with respect to
HIV/AIDS, and to take remedial actions.
Scherer, Frederic M.; and Watal Jayashree. 2001. Post-Trips Options for Access to Patented
Medicines in Developing Countries. CMH Working Paper Series. Commission on
Macroeconomics and Health. http://www.cmhealth.org/docs/wg4_paper1.pdf.
Subramanian, Arvind. 1995. “Putting Some Numbers on the TRIPS Pharmaceutical Debate.”
International Journal of Technology Management 10(2/3): 252-269.
Abstract: Estimates the changes in prices, profits and social welfare arising from increased patent protection for
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incentives are largely externalized to the rest of the developing world. The WTO TRIPS agreement held out some
promise of overcoming part of this problem, but just as the obligations of developing nations under TRIPS were
beginning to take hold, the Doha ministerial declaration casts great doubt on the future credibility of patent rights
for pharmaceuticals in the developing nations.
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